skip to main content

S. 2678 (114th): STOP Pain Act

The text of the bill below is as of Mar 15, 2016 (Introduced).


II

114th CONGRESS

2d Session

S. 2678

IN THE SENATE OF THE UNITED STATES

March 15, 2016

(for himself, Mr. Hatch, Mr. Tester, Mr. Cochran, Ms. Collins, and Ms. Baldwin) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To direct the NIH to intensify and coordinate fundamental, translational, and clinical research with respect to the understanding of pain, the discovery and development of therapies for chronic pain, and the development of alternatives to opioids for effective pain treatments.

1.

Short title

This Act may be cited as the Safe Treatments and Opportunities to Prevent Pain Act or the STOP Pain Act.

2.

Enhancing basic and applied research on pain to discover therapies, including alternatives to opioids, for effective pain management

(a)

In general

The Director of the National Institutes of Health (referred to in this section as the NIH) may intensify and coordinate fundamental, translational, and clinical research of the NIH with respect to—

(1)

the understanding of pain;

(2)

the discovery and development of therapies for chronic pain; and

(3)

the development of alternatives to opioids for effective pain treatments.

(b)

Priority and direction

The prioritization and direction of the federally funded portfolio of pain research studies shall consider recommendations made by the Interagency Pain Research Coordinating Committee in concert with the Pain Management Best Practices Inter-Agency Task Force, and in accordance with the National Pain Strategy, the Federal Pain Research Strategy, and the NIH-Wide Strategic Plan for Fiscal Years 2016–2020, the latter which calls for the relative burdens of individual diseases and medical disorders to be regarded as crucial considerations in balancing the priorities of the Federal research portfolio.